Filing summary
Source and period: The supplied filing is MEI Pharma, Inc.’s Form 10-Q for the quarter ended March 31, 2015 (fiscal third quarter; nine-month year-to-date period). This does not match the request metadata identifying Lite Strategy, Inc. and 2013 Q3. Verify the issuer and reporting period before relying on this summary.
Business context
MEI Pharma is a clinical-stage oncology company with no revenue. Its pipeline includes Pracinostat, ME-344 and PWT143. The financial statements are unaudited; interim results are not necessarily indicative of full-year results.
Financial performance and position
| Metric | Three months ended March 31 | Nine months ended March 31 |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | 2015: $6.8 million; 2014: $5.4 million | 2015: $20.0 million; 2014: $12.9 million |
| General and administrative expense | 2015: $2.2 million; 2014: $2.0 million | 2015: $7.0 million; 2014: $5.8 million |
| Net loss | 2015: $8.9 million; 2014: $7.4 million | 2015: $27.0 million; 2014: $18.6 million |
| Basic and diluted net loss per share | 2015: $0.27; 2014: $0.34 | 2015: $1.03; 2014: $0.95 |
Research and development expense increases primarily reflected Pracinostat manufacturing and trials, ME-344 clinical work, PWT143 preclinical studies, and increased staffing. Higher weighted-average shares, following equity issuance, reduced quarterly loss per share despite a larger net loss; year-to-date loss per share increased.
At March 31, 2015, cash and cash equivalents were $20.5 million and short-term investments were $50.1 million, totaling $70.5 million, up from $48.8 million at June 30, 2014. Total assets were $71.6 million; current liabilities were $6.6 million; stockholders’ equity was $65.0 million. No debt balance is reported in the provided balance sheet. The filing does not present a gross margin or operating margin; the company had no revenue and reported operating losses.
For the nine months, operating cash use was $21.3 million, compared with $13.6 million in 2014; investing cash use was $15.1 million, primarily reflecting short-term investments; financing provided $43.1 million, principally net proceeds from the December 2014 stock offering. Cash and cash equivalents increased by $6.7 million.
Outlook, developments and risks
- Management expected existing cash, cash equivalents and short-term investments to fund operations through at least calendar 2016, while noting that future operating needs may require equity financing or strategic partnerships.
- In March 2015, top-line results from a randomized Phase II Pracinostat-plus-azacitidine MDS study showed no difference in complete-remission rate, its primary endpoint, versus azacitidine alone. Survival and other event-driven outcomes remained immature. The combination group had more fatigue, gastrointestinal toxicity and myelosuppression, with more drug discontinuations; no new toxicities were observed. Management said it would not initiate further Pracinostat/azacitidine studies until it better understood the full data.
- The Pracinostat study in HMA-refractory MDS met its prespecified response threshold for expanding enrollment; three of the first 28 patients had clinical responses. Enrollment in the newly diagnosed elderly AML study was complete, with interim efficacy reported in 33 patients; additional data were expected in June 2015.
- ME-344 combination-trial enrollment continued, with ovarian-cancer cohort data expected in the fourth quarter of calendar 2015. Management expected to begin a first-in-human PWT143 study in mid-2015.
- Key risks include clinical-trial failure or delay, regulatory uncertainty, need for additional financing, manufacturing and development costs, dependence on third-party arrangements, competition, and intellectual-property risks. The company reported no material change to its previously disclosed risk factors and no legal proceedings.
Potential contingent payments to S*Bio include up to $75.2 million tied to regulatory and sales milestones; no amount was accrued at March 31, 2015. The first specified clinical milestone would trigger $200,000 plus company shares valued at $500,000. The office lease was amended in April 2015 to run through June 30, 2016, with an option for one additional year.
Important facts to verify
- Confirm that MEI Pharma’s March 31, 2015 10-Q—not a Lite Strategy filing for 2013 Q3—is the intended source.
- Review the full Pracinostat MDS trial results and subsequent follow-up, particularly secondary endpoints and adverse-event discontinuations.
- Assess the cash runway against ongoing clinical-development spending and the company’s stated expectation of possible future financing.
- Check share-count changes and potential dilution: common shares outstanding rose to 34.2 million from 21.6 million at June 30, 2014, following the December offering.
- Track the S*Bio milestone terms, clinical program timelines, and the stated PWT143 and ME-344 data expectations.